TY - JOUR
T1 - Genomic lesions associated with a different clinical outcome in diffuse large B-cell lymphoma treated with R-CHOP-21
AU - Scandurra, Marta
AU - Mian, Michael
AU - Greiner, Timothy C.
AU - Rancoita, Paola M.V.
AU - De Campos, Cassio P.
AU - Chan, Wing C.
AU - Vose, Julie M.
AU - Chigrinova, Ekaterina
AU - Inghirami, Giorgio
AU - Chiappella, Annalisa
AU - Baldini, Luca
AU - Ponzoni, Maurilio
AU - Ferreri, Andres J.M.
AU - Franceschetti, Silvia
AU - Gaidano, Gianluca
AU - Montes-Moreno, Santiago
AU - Piris, Miguel A.
AU - Facchetti, Fabio
AU - Tucci, Alessandra
AU - Nomdedeu, Josep Fr
AU - Lazure, Thierry
AU - Lambotte, Olivier
AU - Uccella, Silvia
AU - Pinotti, Graziella
AU - Pruneri, Giancarlo
AU - Martinelli, Giovanni
AU - Young, Ken H.
AU - Tibiletti, Maria Grazia
AU - Rinaldi, Andrea
AU - Zucca, Emanuele
AU - Kwee, Ivo
AU - Bertoni, Francesco
PY - 2010/11
Y1 - 2010/11
N2 - Despite recent therapeutic improvements, the clinical course of diffuse large B-cell lymphoma (DLBCL) still differs considerably among patients. We conducted this retrospective multi-centre study to evaluate the impact of genomic aberrations detected using a high-density genome wide-single nucleotide polymorphism-based array on clinical outcome in a population of DLBCL patients treated with R-CHOP-21 (rituximab, cyclophosphamide, doxorubicine, vincristine and prednisone repeated every 21 d). 166 DNA samples were analysed using the GeneChip Human Mapping 250K NspI. Genomic anomalies were analysed regarding their impact on the clinical course of 124 patients treated with R-CHOP-21. Unsupervised clustering was performed to identify genetically related subgroups of patients with different clinical outcomes. Twenty recurrent genetic lesions showed an impact on the clinical course. Loss of genomic material at 8p23.1 showed the strongest statistical significance and was associated with additional aberrations, such as 17p- and 15q-. Unsupervised clustering identified five DLBCL clusters with distinct genetic profiles, clinical characteristics and outcomes. Genetic features and clusters, associated with a different outcome in patients treated with R-CHOP, have been identified by arrayCGH.
AB - Despite recent therapeutic improvements, the clinical course of diffuse large B-cell lymphoma (DLBCL) still differs considerably among patients. We conducted this retrospective multi-centre study to evaluate the impact of genomic aberrations detected using a high-density genome wide-single nucleotide polymorphism-based array on clinical outcome in a population of DLBCL patients treated with R-CHOP-21 (rituximab, cyclophosphamide, doxorubicine, vincristine and prednisone repeated every 21 d). 166 DNA samples were analysed using the GeneChip Human Mapping 250K NspI. Genomic anomalies were analysed regarding their impact on the clinical course of 124 patients treated with R-CHOP-21. Unsupervised clustering was performed to identify genetically related subgroups of patients with different clinical outcomes. Twenty recurrent genetic lesions showed an impact on the clinical course. Loss of genomic material at 8p23.1 showed the strongest statistical significance and was associated with additional aberrations, such as 17p- and 15q-. Unsupervised clustering identified five DLBCL clusters with distinct genetic profiles, clinical characteristics and outcomes. Genetic features and clusters, associated with a different outcome in patients treated with R-CHOP, have been identified by arrayCGH.
KW - Comparative genomic hybridization
KW - Hepatitis C virus
KW - Lymphoma
KW - Microarray
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=79551633868&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2141.2010.08326.x
DO - 10.1111/j.1365-2141.2010.08326.x
M3 - Article
SN - 0007-1048
VL - 151
SP - 221
EP - 231
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 3
ER -
